6 citations
,
May 2020 in “Pharmacology Research & Perspectives” This study in rats found that a new hydroxypropyl-β-cyclodextrin formulation of minoxidil reduced the adverse cardiovascular and proliferative effects seen with traditional minoxidil solutions.
39 citations
,
April 2010 in “International Journal of Pharmaceutics” This study found that using monoolein cubic phase nanoparticles with an entrapped hydroxypropyl β-cyclodextrin/minoxidil complex increased minoxidil skin permeation, but minoxidil retention in the skin was higher with a traditional solution.
19 citations
,
November 2017 in “Journal of Pharmaceutical Sciences” This research investigated aqueous alginate-based hydrogels for delivering minoxidil and reported that using hydroxypropyl-β-cyclodextrin (HP-β-CD) with molar substitution 0.65 significantly enhanced minoxidil's solubility and skin permeability without damaging the epidermis, suggesting potential as an alternative to commercial minoxidil solutions.
19 citations
,
October 2017 in “European Journal of Pharmaceutics and Biopharmaceutics” This study found that the MXD/HP-β-CD GEL formulation promoted greater hair growth and improved gene expression related to hair growth in male rats compared to MXD solution or control groups.
16 citations
,
March 2017 in “Journal of inclusion phenomena and macrocyclic chemistry” This study found that using 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD) to encapsulate minoxidil can create a stable aqueous solution, potentially replacing the need for organic solvents in topical treatments for androgenic alopecia.